SUMMER ROAD LLC
Known title: 10% OwnerCIK: 0001604873
SUMMER ROAD LLC's purchase track record
How the stock did after each of SUMMER ROAD LLC's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
10
of 10 since December 6, 2021
Stock higher 6 months later
50%
3 months: 20%
Median 6-month return
-1.1%
3 months: -23.8%
Beat the S&P 500
50%
median -0.9% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/26/2024 | OCUL | $7.00M | -40.1% | -9.0% | +10.8% |
| 12/14/2023 | OCUL | $5.00M | +144.3% | +33.0% | +15.1% |
| 11/7/2022 | OCUL | $26K | +19.7% | +80.3% | +8.7% |
| 10/10/2022 | OCUL | $79K | -8.9% | +30.4% | +13.8% |
| 9/27/2022 | OCUL | $689K | -38.8% | +17.6% | +8.9% |
| 2/18/2022 | OCUL | $248K | -31.6% | +6.7% | -2.8% |
| 1/21/2022 | OCUL | $332K | -33.5% | -20.5% | -9.9% |
| 1/13/2022 | OCUL | $405K | -28.9% | -30.2% | -18.6% |
| 12/14/2021 | OCUL | $282K | -18.7% | -43.6% | -19.4% |
| 12/6/2021 | OCUL | $644K | -18.3% | -46.4% | -10.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| OCUL | ▲ Buy | Open Market | 930,851 | $7.0M | 2/26/2024 | View on chart |
| OCUL | ▲ Buy | Open Market | 1,538,461 | $5.0M | 12/14/2023 | View on chart |
| OCUL | ▲ Buy | Open Market | 7,328 | $26K | 11/7/2022 | View on chart |
| OCUL | ▲ Buy | Open Market | 10,000 | $39K | 10/11/2022 | View on chart |
| OCUL | ▲ Buy | Open Market | 10,000 | $40K | 10/10/2022 | View on chart |
| OCUL | ▲ Buy | Open Market | 18,800 | $76K | 9/29/2022 | View on chart |
| OCUL | ▲ Buy | Open Market | 1,200 | $5K | 9/28/2022 | View on chart |
| OCUL | ▲ Buy | Open Market | 130,000 | $608K | 9/27/2022 | View on chart |
| OCUL | ▲ Buy | Open Market | 10,000 | $48K | 2/23/2022 | View on chart |
| OCUL | ▲ Buy | Open Market | 40,000 | $200K | 2/18/2022 | View on chart |
| OCUL | ▲ Buy | Open Market | 4,023 | $21K | 1/28/2022 | View on chart |
| OCUL | ▲ Buy | Open Market | 1,477 | $8K | 1/27/2022 | View on chart |
| OCUL | ▲ Buy | Open Market | 44,400 | $236K | 1/24/2022 | View on chart |
| OCUL | ▲ Buy | Open Market | 12,152 | $68K | 1/21/2022 | View on chart |
| OCUL | ▲ Buy | Open Market | 17,948 | $102K | 1/20/2022 | View on chart |
| OCUL | ▲ Buy | Open Market | 6,807 | $41K | 1/18/2022 | View on chart |
| OCUL | ▲ Buy | Open Market | 33,193 | $200K | 1/14/2022 | View on chart |
| OCUL | ▲ Buy | Open Market | 10,000 | $62K | 1/13/2022 | View on chart |
| OCUL | ▲ Buy | Open Market | 15,000 | $93K | 12/15/2021 | View on chart |
| OCUL | ▲ Buy | Open Market | 29,490 | $189K | 12/14/2021 | View on chart |
| OCUL | ▲ Buy | Open Market | 10,510 | $68K | 12/13/2021 | View on chart |
| OCUL | ▲ Buy | Open Market | 30,000 | $199K | 12/10/2021 | View on chart |
| OCUL | ▲ Buy | Open Market | 5,300 | $36K | 12/8/2021 | View on chart |
| OCUL | ▲ Buy | Open Market | 55,600 | $341K | 12/6/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
OCUL: UBS initiates coverage and Nasdaq grant filing reported
UBS has started coverage of Ocular Therapeutix and set a price target of $14. The company also disclosed inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). OCUL presented its latest data at the Euretina 2026 conference, highlighting ongoing development efforts. Analyst commentary this week varies, with some listing the stock among top healthcare picks while others note its unprofitable status.
OCUL: UBS initiates coverage and Nasdaq grant filing reported. UBS has started coverage of Ocular Therapeutix and set a price target of $14. The company also disclosed inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). OCUL presented its latest data at the Euretina 2026 conference, highlighting ongoing development efforts. Analyst commentary this week varies, with some listing the stock among top healthcare picks while others note its unprofitable status.